Ardelyx, Inc. reported its third quarter 2024 financial results, with total revenue reaching $98.2 million, a significant increase from $56.4 million in the same quarter of 2023. This growth was primarily driven by a rise in net product sales, including a 15% quarter-over-quarter increase in IBSRELA sales to $40.6 million and a 39% increase in XPHOZAH sales to $51.5 million. The company also reported a net loss for the quarter, although specific figures were not disclosed. Ardelyx's cash position stood at $190.4 million as of the end of the quarter, bolstered by an additional $50 million secured in funding. The company provided an outlook for full-year 2024, estimating net sales revenue for IBSRELA between $145 million and $150 million, while emphasizing its commitment to maintaining patient access to XPHOZAH amid upcoming changes in Medicare reimbursement policies in January 2025.